


Methacycline hydrochloride

Cat. No.:	HY-B0449
CAS No.:	3963-95-9
Molecular Formula:	C ₂₂ H ₂₃ ClN ₂ O ₈
Molecular Weight:	478.88
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



HCl

SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (104.41 mM; Need ultrasonic)						
	H ₂ O : 6.67 mg/mL (13.93 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.0882 mL	10.4410 mL	20.8821 mL
				5 mM	0.4176 mL	2.0882 mL	4.1764 mL
10 mM				0.2088 mL	1.0441 mL	2.0882 mL	
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	Methacycline hydrochloride is a tetracycline antibiotic and can inhibit bacterial protein synthesis. Methacycline hydrochloride is a potent epithelial-mesenchymal transition (EMT) inhibitor. Methacycline hydrochloride blocks EMT in vitro and fibrogenesis in vivo without directly affecting TGF-β1 Smad signaling. Methacycline hydrochloride is an antimicrobial and has the potential for pulmonary fibrosis ^[1] .
IC ₅₀ & Target	Tetracycline
In Vitro	Methacycline hydrochloride is an inhibitor of A549 EMT with an IC ₅₀ of roughly 5 μM ^[1] . ?In vitro, Methacycline hydrochloride (10, 20 μM; for 48 hours) inhibits TGF-β1-induced α-smooth muscle actin, Snail1, and collagen I of primary alveolar epithelial cells. Methacycline hydrochloride inhibits TGF-β1-induced non-Smad pathways, including c-Jun N-terminal kinase, p38, and Akt activation, but not Smad or β-catenin transcriptional activity. Methacycline has no effect on baseline c-Jun N-terminal kinase, p38, or Akt activities or lung fibroblast responses to TGF-β1 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In vivo, Methacycline hydrochloride (100 mg/kg/day; ip; beginning 10 days after intratracheal Bleomycin) improves survival at Day 17. Bleomycin-induced canonical EMT markers, Snail1, Twist1, collagen I, as well as fibronectin protein and mRNA, ARE attenuated by Methacycline hydrochloride (Day 17)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- EBioMedicine. 2022 Apr;78:103943.
- SLAS Discov. 2020 Sep;25(8):895-905.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ying Xi, et al. Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am J Respir Cell Mol Biol. 2014 Jan;50(1):51-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA